JP2009511559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511559A5 JP2009511559A5 JP2008535097A JP2008535097A JP2009511559A5 JP 2009511559 A5 JP2009511559 A5 JP 2009511559A5 JP 2008535097 A JP2008535097 A JP 2008535097A JP 2008535097 A JP2008535097 A JP 2008535097A JP 2009511559 A5 JP2009511559 A5 JP 2009511559A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- represent
- pharmaceutically acceptable
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102000042256 MAPEG family Human genes 0.000 claims 7
- 108091077604 MAPEG family Proteins 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- -1 —R 3a Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 102100033076 Prostaglandin E synthase Human genes 0.000 claims 4
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims 2
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000003195 fascia Anatomy 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72530105P | 2005-10-12 | 2005-10-12 | |
| PCT/GB2006/003792 WO2007042816A1 (en) | 2005-10-12 | 2006-10-12 | Benzoxazoles useful in the treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511559A JP2009511559A (ja) | 2009-03-19 |
| JP2009511559A5 true JP2009511559A5 (https=) | 2009-12-03 |
Family
ID=36129701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535097A Withdrawn JP2009511559A (ja) | 2005-10-12 | 2006-10-12 | 炎症の治療に有用なベンゾオキサゾール類 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090258917A1 (https=) |
| EP (1) | EP1933834A1 (https=) |
| JP (1) | JP2009511559A (https=) |
| CA (1) | CA2620899A1 (https=) |
| WO (1) | WO2007042816A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080081913A1 (en) * | 2006-09-29 | 2008-04-03 | General Electric Company | Benzoxazole and benzothiazole compounds and methods therefor |
| US20080081210A1 (en) | 2006-09-29 | 2008-04-03 | General Electric Company | Authenticatable articles and methods therefor |
| WO2008071944A1 (en) * | 2006-12-14 | 2008-06-19 | Boehringer Ingelheim International Gmbh | Benzoxazoles useful in the treatment of inflammation |
| WO2009030952A2 (en) * | 2007-09-05 | 2009-03-12 | Astrazeneca Ab | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway |
| WO2009080788A2 (en) * | 2007-12-21 | 2009-07-02 | Universite Catholique De Louvain | Antibacterial agents |
| EP2078711A1 (en) | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| GB201006846D0 (en) | 2010-04-23 | 2010-06-09 | Glaxo Group Ltd | Novel compounds |
| EP2495244A1 (en) | 2011-03-02 | 2012-09-05 | NovaSaid AB | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors |
| EP3604271A1 (en) | 2013-06-28 | 2020-02-05 | Auckland Uniservices Limited | Peptides for amino acid and peptide conjugates and conjugation process |
| US9630937B2 (en) | 2013-11-08 | 2017-04-25 | Promentis Pharmaceuticals, Inc. | Substituted N-acetyl-L-cysteine derivatives and related compounds |
| CN107250103A (zh) | 2014-12-23 | 2017-10-13 | 玛格丽特·安妮·布林布尔 | 氨基酸缀合物和肽缀合物以及其用途 |
| CN104788398B (zh) * | 2015-03-24 | 2017-09-08 | 上海交通大学 | 苯并恶唑类化合物及其制备方法和用途 |
| TW201735952A (zh) | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298189A (en) * | 1992-04-24 | 1994-03-29 | Nanoptics Incorporated | Proton transfer bis-benzazole fluors and their use in scintillator detectors |
| WO2004046122A2 (en) * | 2002-11-16 | 2004-06-03 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
| WO2004080999A1 (en) * | 2003-03-14 | 2004-09-23 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
| JP2007516203A (ja) * | 2003-07-09 | 2007-06-21 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| WO2005030705A1 (en) * | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US20060052425A1 (en) * | 2004-03-23 | 2006-03-09 | Wisconsin Alumni Research Foundation | Method for modulating microbial quorum sensing |
| EP1807074B1 (en) * | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
-
2006
- 2006-10-12 JP JP2008535097A patent/JP2009511559A/ja not_active Withdrawn
- 2006-10-12 WO PCT/GB2006/003792 patent/WO2007042816A1/en not_active Ceased
- 2006-10-12 US US12/083,384 patent/US20090258917A1/en not_active Abandoned
- 2006-10-12 CA CA002620899A patent/CA2620899A1/en not_active Abandoned
- 2006-10-12 EP EP06794740A patent/EP1933834A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511559A5 (https=) | ||
| CA2475712C (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| RU2160257C2 (ru) | Способ получения фенильных гетероциклов и промежуточное соединение | |
| TWI268925B (en) | 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
| RU2007101703A (ru) | Индолы, полезные при лечении воспаления | |
| CA2539909A1 (en) | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo(2,3-c) pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | |
| JP2010520268A5 (https=) | ||
| JP2005539054A5 (https=) | ||
| CN110357789B (zh) | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 | |
| JP2006520373A5 (https=) | ||
| CA2656415A1 (en) | Novel pyridazine compound and use thereof | |
| CA2513081A1 (en) | Pyrrolopyridazine derivatives | |
| JP2005522449A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| JP2010516701A5 (https=) | ||
| RU2007101705A (ru) | Индолы, полезные для лечения воспаления | |
| JP2008502670A5 (https=) | ||
| JP2023518775A5 (https=) | ||
| JP2007522111A5 (https=) | ||
| RU2013107759A (ru) | Производные оксадиазола и пиридазина, их получение и применение в терапии | |
| CN101300236A (zh) | 作为脂肪加氧酶抑制剂的三唑化合物 | |
| JPH032173A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| JP2004517088A5 (https=) | ||
| JP2005529084A (ja) | 結晶性パレコキシブナトリウム | |
| KR101536488B1 (ko) | 이미다졸 유도체, 그의 제조 방법 및 용도 | |
| JP2009513690A (ja) | 炎症の治療に有用なピラゾール類 |